Oral News and Research

RSS

Basilea Pharmaceutica expands potential commercial availability of Toctino in Europe

Basilea Pharmaceutica Ltd. has announced the submission of a Marketing Authorization Application (MAA) for Toctino (alitretinoin) in 13 additional European Union (EU) Member States as well as in Norway and Iceland. Toctino is a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids.

31 Mar 2009

Schizophrenics at increased risk for type 2 diabetes

People with schizophrenia are at increased risk for type 2 diabetes, Medical College of Georgia researchers have found.

30 Mar 2009

Improving cancer therapy achieved through taste, odor intervention

Cancer and its therapies, including chemotherapy and radiotherapy, may directly alter and damage taste and odor perception, possibly leading to patient malnutrition, and in severe cases, significant morbidity, according to a Virginia Tech - Wake Forest University Comprehensive Cancer Center compilation of various existing studies.

30 Mar 2009

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.

30 Mar 2009

High dosage brachytherapy obtains excellent results in head and neck tumors

High-dosage perioperative brachytherapy (applied within the surgical process) obtains excellent results in the treatment of head and neck tumours, at the same time as reducing the period of radiation.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Transdermal delivery of estrogen therapy may show safety benefits as opposed to oral delivery

Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests.

29 Mar 2009

Orexo reports on efficacy study in allergic rhinitis with OX914

Orexo has reported clinical results from an experimental phase IIa safety and efficacy study in allergic rhinitis with OX914, the first compound in its Phosphodiesterase 4 (PDE4) inhibitor program.

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Africa's ongoing cholera epidemic "unconscionable"

Although illness rates and mortality from cholera have been drastically reduced in a vast majority of the world, Africa remains plagued by soaring cases and deaths from the waterborne intestinal disease.

24 Mar 2009

Family history linked to increased risk of venous thrombosis

Children and siblings of those with venous thrombosis, or blood clots in the veins, appear to have more than double the risk of developing the condition than those without a family history, according to a report in the March 23 issue of Archives of Internal Medicine.

23 Mar 2009

Warner Chilcott files new lawsuit for infringement of DORYX patent

Warner Chilcott Limited has announced hat one of its subsidiaries and Mayne Pharma International Pty. Ltd. ("Mayne") have filed a second lawsuit against Impax Laboratories, Inc. ("Impax") in the District Court for the District of New Jersey for infringement of Mayne's U.S. Patent No. 6,958,161 (the "'161 Patent") which covers DORYX, a tetracycline-class oral antibiotic.

20 Mar 2009

Research yields potential target for cancer, wound healing and fibrosis

Research conducted by Allison Berrier, PhD, Assistant Professor of Oral and Craniofacial Biology at the LSU Health Sciences Center New Orleans School of Dentistry, and colleagues, provides insights that may help scientists design novel approaches to control wound healing and fight diseases such as cancer and fibrosis.

20 Mar 2009

Naltrexone can reduce relapse rates among alcohol-dependence patients

Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients.

20 Mar 2009

A silicone ear

To look at Matthew Houdek, you could never tell he was born with virtually no left ear.

17 Mar 2009

Metabolic syndrome can help identify diabetes risk in Aboriginal Canadians

Metabolic syndrome is the clustering of risk factors associated with diabetes and heart disease, such as obesity, high cholesterol, high glucose and hypertension.

16 Mar 2009

MannKind Corporation submits NDA for Afresa for treatment of diabetes

MannKind Corporation has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Afresa (insulin monomer human [rDNA origin]) Inhalation Powder and the Afresa Inhaler for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.

16 Mar 2009

Children can complete treatment for peanut allergies and achieve long-term tolerance

A carefully administered daily dose of peanuts has been so successful as a therapy for peanut allergies that a select group of children is now off treatment and eating peanuts daily, report doctors at Duke University Medical Center and Arkansas Children's Hospital.

15 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Childhood diarrhoea needs greater research focus

The list of priority research questions focus on how to make the best use of interventions that are available today, in order to make the most difference, and ultimately save as many children's lives as possible.

11 Mar 2009